BB Biotech’s bet on a positive US regulatory review of Biogen’s controversial Alzheimer’s disease therapy aducanumab is poised for its denouement, with the PDUFA date – the deadline for the FDA to render an approval decision – now less than two weeks away. The Swiss investment firm acquired a stake in Biogen (accounting for 3.3% […]
Swiss investor BB Biotech made two new investments in the first quarter in US small caps – Essa Pharma and Revolution Medicines – while exiting its positions in Cidara Therapeutics and Voyager Therapeutics, according to its portfolio update published earlier today. Essa Pharma (Nasdaq: EPIX) is developing a small molecule drug, EPI-7386, in metastatic castration-resistant […]
Investment trust insider on biotech and healthcare – James Carthew: Why I will stick with biotech after Covid It is now a year since the market meltdown triggered by the coronavirus. Just beforehand, I wrote an article exploring Orbimed’s thoughts on the US election’s potential impact on the healthcare sector. The manager of the Biotech Growth […]
A leading biotech investor BB Biotech is the oldest-established, the largest and, over the longer term, one of the best-performing of the small group of closed-end funds that specialise in the biotech sector. It offers investors a vehicle to gain exposure to a focused portfolio of predominantly-US small-to-mid-cap biotech companies developing therapeutic products, with a […]
Bold Brilliant biotech investor BB Biotech is the oldest-established, the largest and, over the longer term, one of the best-performing of the small group of closed-end funds that specialise in the biotech sector. It offers investors a vehicle to gain exposure to a focused portfolio of predominantly-US small-to-mid-cap biotech companies developing therapeutic products, with a […]
Bold Brilliant biotech investor Swiss-listed BB Biotech is the oldest-established, the largest and, over the longer term, one of the best-performing of the small group of closed-end funds that specialise in the biotech sector. It offers investors a vehicle to gain exposure to a focused portfolio of predominantly-US small-to-mid-cap biotech companies developing therapeutic products, with […]
Baillie Gifford US Growth’s (USA) interim results to 30 November 2020 brought share price and NAV returns of 50.8% and 53.8%. This compares with a total return of 11.1% for the S&P 500 index (in sterling terms). Some of the highlights from the period include: Moderna, held by USA since 2018, is one of the biotechnology companies […]
International Biotechnology Trust (IBT) has delivered strong returns over the past 12 months, with the NAV up 30% over the year to date, well ahead of its benchmark, and wider national and global indices. The COVID-19 pandemic has focused attention on the sector as a number of companies search for effective treatments and vaccines. The […]
International Biotechnology Trust (IBT) has delivered strong returns over the past year; its net asset value (NAV) is up 30% over the year to date, well ahead of its benchmark, and wider national and global indices. The COVID-19 pandemic has focused attention on the sector as a number of companies search for effective treatments and […]
International Biotechnology Trust (IBT) has delivered strong returns over the past year, the NAV is up 30% over the year to date, well ahead of its benchmark, and wider national and global indices. The pandemic has focused attention on the sector as a number of companies search for effective treatments and vaccines. The sector has […]
Please review our cookie, privacy & data protection and terms and conditions policies and, if you accept, please select your place of residence and whether you are a private or professional investor.
Due to data protection policies, USA residents can not access our data.
Your content has been curated
